Immuneering reports 17.3-month survival in pancreatic cancer trial
Go back to Immuneering reports 17.3-month survival in pancreatic cancer trial| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.54 +0.10 (2.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.44 | 52 Week High | $0.04 | |||
| Open | $4.38 | 52 Week Low | $0.00 | |||
| Day High | $4.67 | P/E | N/A | |||
| Day Low | $4.38 | EPS | $-0.09 | |||
| Volume | 935,464 | |||||
| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 33.21 +1.01 (3.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.20 | 52 Week High | $66.55 | |||
| Open | $32.14 | 52 Week Low | $37.82 | |||
| Day High | $33.34 | P/E | N/A | |||
| Day Low | $32.12 | EPS | $0.00 | |||
| Volume | 5,566,781 | |||||
